General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Amgen(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), Abbvie(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Actavis(SIGNIFICANT), Amarin(SIGNIFICANT), Caladrius(SIGNIFICANT), Casana(SIGNIFICANT), CSL Behring(SIGNIFICANT), Cytokinetics(NONE), Imara(SIGNIFICANT), Eli Liily(SIGNIFICANT), Reata(SIGNIFICANT), Relypsa(MODEST), Salamandra(SIGNIFICANT), Moderna(SIGNIFICANT), Alnylam(SIGNIFICANT), ARMGO(SIGNIFICANT), Ardelyx(SIGNIFICANT), Biopeutics(SIGNIFICANT), Casana(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Pharmacosmos(SIGNIFICANT), Regeneron(NONE), 89bio(MODEST)

View Full Disclosure